Presentation fees: $3000 （Includes presentation fee and one registration for presenter）
Presentation Companies Can:
- Meet pre-vetted decision makers from top Chinese pharma and investment firms
- Know your audience prior to the pitch
- Maximized your company visibility through pre-conference promotion
- Present for 8min with Powerpoint
- Schedule immediate follow-up meetings through on-target partnering
• Drug development
• Platform technology
• Medical device
• Digital health
Opportunities our audience are seeking
• Joint Venture
• And more…
Description: A leading biopharmaceutical company based in China with annual sales of $2.2 billion in 2017 and a market cap of $31 billion.
Recent Deal: Mycovia and Hengrui Medicine have signed an agreement to develop and commercialise the former’s investigational drug, VT-1161 for RVVC
Interests: oncology, autoimmune, metabolic and CV
Recent Deal: Verastem grants CSPC exclusive rights to develop and commercialize the cancer drug Copiktra duvelisib in China.
Interests: Oncology, CV, Autoimmune
Description: Established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform.
Recent Deal: Revance Therapeutics grants Fosun exclusive Chinese rights to RT002.
Interests: oncology, cardiovascular disease, CNS, liver disease, medical device
Description: Salubris is a globally integrated pharmaceutical group dedicated to the research, development, manufacture, marketing, distribution.
Recent Deal: Viracta Therapeutics Inc. granted Salubris exclusive rights to develop and sell its virus-related cancer therapy nanatinostat/valganciclovir in the great China.
Interests: Oncology, CV and metabolic diseases
Description: Luye Pharma is an international pharmaceutical company with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas.
Recent Deal: Luye Pharma and PharmaMar Sign Licensing Agreement for the Development and Commercialization of Zepsyre® in China.
Interests: Oncology, CNS, CV, diabetes, digestive disease and metabolic diseases
Description: A fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines, with annual revenue of 4.5 billion USD.
Recent Deal: Huadong Medicine Co Ltd. Gains Access to Sinclair Pharma’s Highly Differentiated Aesthetics Products to Expand Business Beyond China into United States and Other Markets
Interests: Diabetes, Aesthetics, autoimmune disease, digestive disease, CV, oncology, and infectious disease.
CEO ARIZ Precision Medicine
I attended and presented my company at the Pitch&Match session conducted by MyBioGate at the JPM week in SF. In all the decades that I have been involved in partnering and fund-raising, I must say that the private pitch session was the most efficient and productive 8 minute presentation I have ever made, due in large part to how Ginger and her associates at MyBioGate executed this program. I also saw how this program worked for many other CEOs, in obtaining instant meetings with investors and medical company executives. Amazing! For me, this meeting and the associated networking enabled me to meet and talk with Starlink Capital, JITRI, PHARSCIN PHARMA, Cedrus Group, Accent, ANLONG, LIVZON, LILLY, BAYER, PFIZER, AISLING, KATAI CAPITAL, CELLO HEALTH, SHENZHEN SHIYU INVESTMENT, QILU PHARMA and BUTTON CAPITAL. A great meeting and MyBioGate team effort to be sure!